Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines

Dover, DE, Nov. 07, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) (“AlphaTON”) and its wholly owned oncology subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (“Cyncado”), today announced a poster presentation at the Society for Immunotherapy of Cancer Annual Meeting, taking place November 5 to 9, 2025, in National Harbor, Maryland. The poster reports preclinical findings from work conducted by investigators at the National Cancer Institute (NCI) at NCI laboratories. In these studies, NCI researchers evaluated combinations of selective adenosine A2B antagonism (TT-4) and A2A antagonism (TT-10) with antigen-specific cancer vaccines.

Read more at globenewswire.com